Role of CD40-CVD40L in mouse severe malaria

P F Piguet1, C D Kan, C Vesin

  • 1Department of Pathology, University of Geneva, 1 rue M. Servet, CMU, 1211 Geneva, Switzerland. pierre.piguet@medecine.unige.ch

Insights

The CD40-CD40L pathway is crucial for severe malaria mortality in mice. Blocking this interaction significantly reduced deaths by preventing blood-brain barrier damage and macrophage sequestration.

Area of Science:

  • Immunology
  • Pathology
  • Infectious Diseases

Background:

  • Severe malaria poses a significant global health threat.
  • The CD40-CD40L pathway plays a role in immune responses.
  • Understanding molecular mechanisms of malaria pathogenesis is critical.

Purpose of the Study:

  • To investigate the role of the CD40-CD40L (CD154) pathway in severe malaria induced by Plasmodium berghei anka infection in mice.
  • To determine how CD40-CD40L interaction influences mortality, parasite levels, and organ-specific pathology.

Main Methods:

  • Comparison of mortality rates, parasitemia, and blood-brain barrier integrity in wild-type, CD40-deficient, and CD40L-deficient mice infected with Plasmodium berghei anka.
  • Assessment of macrophage and parasitized red blood cell sequestration in brain and lung tissues.
  • Analysis of CD54 expression and tumor necrosis factor plasma levels.

Main Results:

  • Mortality was significantly reduced in CD40- or CD40L-deficient mice compared to wild-type controls (>90% vs. decreased mortality).
  • Parasitemia remained similar across groups, indicating CD40-CD40L is not essential for parasite control.
  • CD40 deficiency prevented blood-brain barrier breakdown and reduced macrophage sequestration in the brain and lungs.
  • Thrombocytopenia was less severe in CD40-deficient mice.

Conclusions:

  • The CD40-CD40L interaction is essential for mortality in severe malaria.
  • This pathway contributes to critical pathological events including blood-brain barrier disruption, macrophage sequestration, and platelet consumption.
  • Targeting the CD40-CD40L pathway may offer a therapeutic strategy for severe malaria.